Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Sleeping Beauty technique helps identify genes responsible for NAFLD-associated liver cancer

With an estimated twenty-thousand protein-coding genes in the human genome, pinpointing a specific gene or pathway responsible for a particular disease can be like finding a needle in the proverbial haystack.

17 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

Ipsen announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, provided a positive opinion for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib.

21 Sep 2018

UK and European research collaborations receive vote of confidence by three major cancer charities

UK and European research collaborations in cancer research have received a vote of confidence by three major cancer charities, with an announcement today of approximately £30 million into six international projects.

20 Sep 2018

Cellular environment affects type of tumor development

Liver cancer is the second leading cause of cancer death worldwide. Two different forms of primary liver cancer cover the majority of cases: About 10 to 20 percent of those affected develop a bile duct carcinoma within the liver (intrahepatic cholangiocellular carcinoma; ICC), the far higher proportion of liver cancers are hepatocellular carcinomas.

12 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Novel approaches for personalized risk prognosis and individualized treatment of NAFLD

More and more adults - but also about 34 percent of obese children - suffer from non-alcoholic fatty liver disease. An unhealthy lifestyle with little physical activity and a diet high in fat, sugar and fructose and/or a genetic predisposition can be the underlying caus.

31 Aug 2018

Researchers discover mechanism that steers growth of cancer cells in melanoma and liver cancer

Melanoma and liver cancer are becoming more widespread in Europe and the US. Whilst both diseases progress very differently, they are among the types of cancer which are most likely to be fatal in the Western world.

29 Aug 2018

Study suggests new strategies for using cell metabolism to treat cancer

Researchers at the University of Cincinnati College of Medicine have discovered that cell metabolism plays an important role in the ability of cells to start a survival program called autophagy, an unwanted side effect of some anti-cancer drugs that helps some tumor cells dodge treatment and eventually regrow into new tumors.

29 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

New drug delivery system delivers anticancer drugs that reduce tumor size

Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.

9 Aug 2018

Scientists develop novel peptide drug that could potentially stop development of liver cancer

A research team led by scientists from the Cancer Institute of Singapore at the National University of Singapore has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma or primary liver cancer.

2 Aug 2018

Alcohol-related cirrhosis mortality on the rise among young adults

Deaths from cirrhosis rose in all but one state between 1999-2016, with increases seen most often among young adults, a new study shows.

19 Jul 2018

Can-Fite BioPharma receives Australian and Chinese patents for new drug to treat erectile dysfunction

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."

17 Jul 2018

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that U.S. researchers published scientific findings recommending development of anti-Liver Cancer Drugs based on a mechanism of action utilized by Namodenoson.

2 Jul 2018

Streamlining and translating basic science discoveries into the clinic

To make sure that good ideas to enhance healthcare are not lost due to a lack of resources, a growing number of centers at Penn Medicine organize forums to pitch ideas to improve medical devices and technology, hold annual competitions to fund studies to improve patient care while keeping costs down, and sponsor seed grants for programs focused on patients who need individualized tailoring of their treatment.

2 Jul 2018

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy.

19 Jun 2018

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced preliminary results from its ongoing Phase I study of small activating RNA candidate MTL-CEBPA in advanced liver cancer.

4 Jun 2018

Scientists reveal role of lung scavenger cells in liver cancer spread to the lungs

Hepatocellular carcinoma is the most common form of liver cancer, and the third biggest cause of death from cancer worldwide.